{"id":"W3087464965","doi":"10.1056/nejmoa2002788","title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1479,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Foundation Medicine; Pharmacyclics; Novartis Pharma; EMD Serono; Genentech; LEO Pharma; Bavarian Nordic; Ipsen; Janssen Pharmaceuticals; AstraZeneca Australia; Astellas Pharma; Eisai; Bayer HealthCare; GlaxoSmithKline; UroGen Pharma; Takeda Oncology; Mirati Therapeutics; University of Patras; Clovis Oncology; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Janssen Biotech; Les Laboratories Pierre Fabre; Massachusetts Medical Society; Advanced Accelerator Applications; Merck KGaA; Endocyte; Pfizer; Incyte; Progenics Pharmaceuticals; Genesis Pharma; Yale University; Exelixis; Sanofi; Amgen; Heron Therapeutics; EUSA Pharma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Avelumab; Urothelial carcinoma; Metastatic Urothelial Carcinoma; Chemotherapy; Oncology; Medicine; Internal medicine; Carcinoma; Standard of care; Immunotherapy; Cancer; Bladder cancer; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05678166625801688,"score_gpt":0.3231609399121029,"score_spread":0.266379273654086,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}